TY - JOUR
KW - Humans
KW - *Anti-Arrhythmia Agents/therapeutic use
KW - *Anticonvulsants/therapeutic use
KW - Electronics
KW - Primary health care
KW - Retrospective Studies
KW - *Neoplasms/drug therapy
KW - *Sodium Channel Blockers/therapeutic use
KW - Breast tumours
KW - Clinical pharmacology
KW - epilepsy
KW - Oncology
AU - C. Fairhurst
AU - F. Martin
AU - I. Watt
AU - M. Bland
AU - T. Doran
AU - W. Brackenbury
AD - Health Sciences, University of York, York, UK.
University of Queensland, Brisbane, Queensland, Australia.
Department of Biology, University of York, York, UK william.brackenbury@york.ac.uk.
AN - 36737094
BT - BMJ Open
C2 - PMC9900071
DO - 10.1136/bmjopen-2022-064376
DP - NLM
ET - 2023/02/04
LA - eng
M1 - 2
N1 - 2044-6055
Fairhurst, Caroline
Martin, Fabiola
Watt, Ian
Bland, Martin
Doran, Tim
Brackenbury, William John
Orcid: 0000-0001-6882-3351
G1000508/Medical Research Council/United Kingdom
Wellcome Trust/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ Open. 2023 Feb 3;13(2):e064376. doi: 10.1136/bmjopen-2022-064376.
PY - 2023
SN - 2044-6055
EP - e064376
T2 - BMJ Open
TI - Sodium channel-inhibiting drugs and cancer-specific survival: a population-based study of electronic primary care data
VL - 13
ER -